Genocea Biosciences Inc. (NASDAQ:GNCA)’s share price shot up 5.3% during mid-day trading on Wednesday . The company traded as high as $4.20 and last traded at $4.19, with a volume of 113,984 shares trading hands. The stock had previously closed at $3.98.

A number of brokerages have recently issued reports on GNCA. Zacks Investment Research downgraded shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. FBR & Co reiterated a “buy” rating on shares of Genocea Biosciences in a report on Friday, June 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $18.13.

The firm’s 50-day moving average is $4.17 and its 200-day moving average is $4.28. The firm’s market capitalization is $127.96 million.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.05. Analysts anticipate that Genocea Biosciences Inc. will post ($1.74) earnings per share for the current fiscal year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.